• Sight Sciences director Staffan Encrantz bought 14,100 common shares at a weighted average price of USD 4.88.
• Direct holdings rose to 1,434,283 shares following the purchase.
• Separate indirect positions were reported at 632,456 shares held in a trust, 5,086,920 shares held through an investment fund.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-267752), on June 11, 2026, and is solely responsible for the information contained therein.